
GeneMind Raises Nearly RMB 400M in Series C Funding Round
GeneMind has raised nearly RMB 400 million in a Series C funding round, which it will put toward expanding the research and development of its products and applications, broadening the
From the company’s inception, GeneMind aimed at the research and development of the DNA sequencer: the core instrument of the modern molecular diagnostics. Genemind is committed to building a precision medical ecosystem that serves healthcare through collaborations with genetic testing service providers and medical institutions.
GeneMind has raised nearly RMB 400 million in a Series C funding round, which it will put toward expanding the research and development of its products and applications, broadening the
On November 28, GeneMind officially launched the third self-developed sequencing system FASTASeq 300. GeneMind showcased the instrument at Medlab Middle East 2023, making its first worldwide debut at booth Z1.B39,
On March, GeneMind and Nanjing Jiangbei New District have reached a strategic partnership. The cooperation mainly focuses on promoting the industrialization and development of high-throughput sequencing technology. The two parties